Literature DB >> 23685781

Gamma delta T cells are activated by polysaccharide K (PSK) and contribute to the anti-tumor effect of PSK.

Carol Inatsuka1, Yi Yang, Ekram Gad, Lauren Rastetter, Mary L Disis, Hailing Lu.   

Abstract

Polysaccharide K (PSK) is a widely used mushroom extract that has shown anti-tumor and immunomodulatory effects in both preclinical and clinical studies. Therefore, it is important to understand the mechanism of actions of PSK. We recently reported that PSK can activate toll-like receptor 2 and enhances the function of NK cells. The current study was undertaken to study the effect of PSK on gamma delta (γδ) T cells, another important arm of the innate immunity. In vitro experiments using mouse splenocytes showed that γδ T cells produce IFN-γ after treatment with PSK and have up-regulated expression of CD25, CD69, and CD107a. To investigate whether the effect of PSK on γδ T cells is direct or indirect, purified γδ T cells were cultured either alone or together with bone marrow-derived DC in a co-culture or trans-well system and then stimulated with PSK. Results showed that direct cell-to-cell contact between γδ T cells and DC is required for optimal activation of γδ T cells. There was also reciprocal activation of DC by PSK-activated γδ T cells, as demonstrated by higher expression of costimulatory molecules and enhanced production of IL-12 by DC in the presence of γδ T cells. PSK can also co-stimulate γδ T cells with anti-TCR and anti-CD3 stimulation, in the absence of DC. Finally, in vivo treatment with PSK activates γδ T cells among the tumor infiltrating lymphocytes, and depleting γδ T cells during PSK treatment attenuated the anti-tumor effect of PSK. All together, these results demonstrated that γδ T cells are activated by PSK and contribute to the anti-tumor effect of PSK.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23685781      PMCID: PMC3727629          DOI: 10.1007/s00262-013-1436-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  46 in total

1.  Regulation of cutaneous malignancy by gammadelta T cells.

Authors:  M Girardi; D E Oppenheim; C R Steele; J M Lewis; E Glusac; R Filler; P Hobby; B Sutton; R E Tigelaar; A C Hayday
Journal:  Science       Date:  2001-09-20       Impact factor: 47.728

2.  Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

Authors:  Francesco Dieli; David Vermijlen; Fabio Fulfaro; Nadia Caccamo; Serena Meraviglia; Giuseppe Cicero; Andrew Roberts; Simona Buccheri; Matilde D'Asaro; Nicola Gebbia; Alfredo Salerno; Matthias Eberl; Adrian C Hayday
Journal:  Cancer Res       Date:  2007-08-01       Impact factor: 12.701

3.  High prevalence of complementary and alternative medicine use among cancer patients: implications for research and clinical care.

Authors:  Barrie R Cassileth; Andrew J Vickers
Journal:  J Clin Oncol       Date:  2005-02-22       Impact factor: 44.544

Review 4.  Modulation of γδ T cell responses by TLR ligands.

Authors:  Daniela Wesch; Christian Peters; Hans-Heinrich Oberg; Kathrin Pietschmann; Dieter Kabelitz
Journal:  Cell Mol Life Sci       Date:  2011-05-11       Impact factor: 9.261

Review 5.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

6.  Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.

Authors:  Hirohito Kobayashi; Yoshimasa Tanaka; Junji Yagi; Yukinari Osaka; Hayakazu Nakazawa; Takehiko Uchiyama; Nagahiro Minato; Hiroshi Toma
Journal:  Cancer Immunol Immunother       Date:  2006-07-19       Impact factor: 6.968

7.  Immunoediting of cancers may lead to epithelial to mesenchymal transition.

Authors:  Keith L Knutson; Hailing Lu; Brad Stone; Jennifer M Reiman; Marshall D Behrens; Christine M Prosperi; Ekram A Gad; Arianna Smorlesi; Mary L Disis
Journal:  J Immunol       Date:  2006-08-01       Impact factor: 5.422

Review 8.  Interleukin-12 and the regulation of innate resistance and adaptive immunity.

Authors:  Giorgio Trinchieri
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

9.  Phase 1 Clinical Trial of Trametes versicolor in Women with Breast Cancer.

Authors:  Carolyn J Torkelson; Erin Sweet; Mark R Martzen; Masa Sasagawa; Cynthia A Wenner; Juliette Gay; Amy Putiri; Leanna J Standish
Journal:  ISRN Oncol       Date:  2012-05-30

10.  Gamma delta T cells provide an early source of interferon gamma in tumor immunity.

Authors:  Yunfei Gao; Wancai Yang; Meng Pan; Eileen Scully; Michael Girardi; Leonard H Augenlicht; Joe Craft; Zhinan Yin
Journal:  J Exp Med       Date:  2003-08-04       Impact factor: 14.307

View more
  2 in total

Review 1.  Insights into the Relationship between Toll Like Receptors and Gamma Delta T Cell Responses.

Authors:  Asif Amin Dar; Rushikesh Sudam Patil; Shubhada Vivek Chiplunkar
Journal:  Front Immunol       Date:  2014-07-31       Impact factor: 7.561

2.  Increase in liver γδ T cells with concurrent augmentation of IFN-β production during the early stages of a mouse model of acute experimental hepatitis B virus infection.

Authors:  Lin Chang; Lei Wang; Ning Ling; Hui Peng; Min Chen
Journal:  Exp Ther Med       Date:  2019-11-13       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.